TY - JOUR
T1 - Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination
AU - Polonis, Victoria R.
AU - Brown, Bruce K.
AU - Borges, Andrew Rosa
AU - Zolla-Pazner, Susan
AU - Dimitrov, Dimiter S.
AU - Zhang, Mei Yun
AU - Barnett, Susan W.
AU - Ruprecht, Ruth M.
AU - Scarlatti, Gabriella
AU - Fenyö, Eva Maria
AU - Montefiori, David C.
AU - McCutchan, Francine E.
AU - Michael, Nelson L.
N1 - Funding Information:
This work was supported in part by Cooperative Agreement no. DAMD17-93-V-3004, between the U.S. Army Medical Research and Material Command and the Henry M. Jackson Foundation for the Advancement of Military Medicine, working with the Division of AIDS, National Institute for Allergy and Infectious Diseases National Institutes of Health. Funding also came in part from the National Cancer Institute, National Institutes of Health, under contract N01-CO-12400 and the Intramural Research Program of the NIH, NCI. We would like to thank Dr. John Mascola for the generous gift of 10 pseudovirus clones. We would also like to thank Tammy Oblander, Lindsay Wieczorek, Erik Odom and Kara Lombardi for their help with the neutralization assays. We also thank Eric Sanders-Buell, Sodsai Tovanabutra and Julie Horak for sequencing and cloning. The views and content expressed are those of the authors and should not be construed to represent the positions of the US Army, the Dept of Defense or the Dept of Health and Human Services.
Funding Information:
In addition, in 2005, a standardized approach to the measurement of neutralizing antibodies for vaccine trials was proposed as a result of meetings convened by the Laboratory Standardization Subcommittee for the Global HIV/AIDS Vaccine Enterprise (GHAVE) ( Mascola et al., 2005 ). This standardization of approaches to monitor the function(s) of vaccine-induced antibodies is reflected in the methodologies currently being employed and investigated through the efforts of the co-investigators of the “Comprehensive Antibody Vaccine Immuno-Monitoring Consortium (CA-VIMC)”, centered at Duke University Medical Center and funded by The Bill and Melinda Gates Foundation in July of 2006. A global workshop, entitled “Standardisation of HIV Neutralisation Assays for Use in Vaccine Research and Clinical Trials”, was convened on March 17–18, 2007 in Varese, Italy, by members of the WHO and the European Commission for HIV Vaccine Research (Meeting report in preparation). A recent summary meeting on “Humoral Immune Responses to HIV and Approaches to Design Antigens that Induce Neutralizing and Other Potentially Protective Antibodies” was also sponsored by the GHAVE in Reston, VA, USA on May 14–15, 2007 ( Montefiori et al., 2007 ). Thus, significant levels of effort and resources have now been committed to the evaluation and implementation of platforms for assessing vaccine-induced antibodies.
PY - 2008/6/5
Y1 - 2008/6/5
N2 - In AIDS vaccine development the pendulum has swung towards a renewed emphasis on the potential role for neutralizing antibodies in a successful global vaccine. It is recognized that vaccine-induced antibody performance, as assessed in the available neutralization assays, may well serve as a "gatekeeper" for HIV-1 subunit vaccine prioritization and advancement. As a result, development of a standardized platform for reproducible measurement of neutralizing antibodies has received considerable attention. Here we review current advancements in our knowledge of the performance of different types of antibodies in a traditional primary cell neutralization assay and the newer, more standardized TZM-bl reporter cell line assay. In light of recently revealed differences (see accompanying article) in the results obtained in these two neutralization formats, parallel evaluation with both platforms should be contemplated as an interim solution until a better understanding of immune correlates of protection is achieved.
AB - In AIDS vaccine development the pendulum has swung towards a renewed emphasis on the potential role for neutralizing antibodies in a successful global vaccine. It is recognized that vaccine-induced antibody performance, as assessed in the available neutralization assays, may well serve as a "gatekeeper" for HIV-1 subunit vaccine prioritization and advancement. As a result, development of a standardized platform for reproducible measurement of neutralizing antibodies has received considerable attention. Here we review current advancements in our knowledge of the performance of different types of antibodies in a traditional primary cell neutralization assay and the newer, more standardized TZM-bl reporter cell line assay. In light of recently revealed differences (see accompanying article) in the results obtained in these two neutralization formats, parallel evaluation with both platforms should be contemplated as an interim solution until a better understanding of immune correlates of protection is achieved.
KW - Antibodies
KW - Human immunodeficiency virus type 1 (HIV-1)
KW - Neutralization assays
KW - Pseudovirus
KW - Standardization
KW - Vaccine immune assessment
UR - http://www.scopus.com/inward/record.url?scp=43249120426&partnerID=8YFLogxK
U2 - 10.1016/j.virol.2008.02.007
DO - 10.1016/j.virol.2008.02.007
M3 - Short survey
C2 - 18367229
AN - SCOPUS:43249120426
SN - 0042-6822
VL - 375
SP - 315
EP - 320
JO - Virology
JF - Virology
IS - 2
ER -